TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05746117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia Device
Description: The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper arm cuff
Description: A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
Study: NCT05486832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve TR valve replacement System
Description: The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
Study: NCT05187741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile health (mHealth)
Description: A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months).
Study: NCT05044663

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study
Study: NCT05285072

Intervention type: RADIATION
Intervention: PET-CT scan
Description: PET-CT scan using 68Ga-DFO

Intervention type: RADIATION
Intervention: PET-CT scan
Description: PET-CT scan using 68Ga-DFO
Study: NCT06365112

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy assisted
Description: Endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy assisted
Description: Endoscopy
Study: NCT04820621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runcaciguat (BAY1101042)
Description: Given as 1 x 15 mg modified release \[MR\] tablet
Study: NCT01353482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
Study: NCT06749912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low back pain wrap
Description: The low back pain wrap device includes heat, vibration, and red light to assist with reducing pain sensation, improving function.
Study: NCT06748482

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: a 15-minute-consultation session with the clinical pharmacist will include detailed and personalized advice on how each patient should take his prescribed medications, the best time to take them, the possible drug-drug interactions, the possible adverse effects such as post operative nausea and vomiting (PONV), bleeding, fever and infection and the required action. A written paper outlining the main points including the detailed protocol with times and doses will be handed to the patient at the end of the consultation. Moreover, a recorded voice note with the detailed protocol will be sent to the patients via the WhatsApp application
Study: NCT06751329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM002
Description: An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM002
Description: An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
Study: NCT01353482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
Study: NCT05198089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use MyInspiration website
Study: NCT06076759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine or dexmedetomidine
Description: Intrathecal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine or dexmedetomidine
Description: Intrathecal injection
Study: NCT05256277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT101a
Description: cytokine-induced memory-like NK cells
Study: NCT05493865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)
Description: This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)
Description: This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.
Study: NCT06434103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921；Adebrelimab；SHR-8068；carboplatin
Description: SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
Study: NCT04741529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program app
Description: The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program app
Description: The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP.
Study: NCT05966987

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin
Description: laser and platelet rich fibrin
Study: NCT04941131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate, povidone iodine
Description: This is a mouth wash that can be used over the counter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate, povidone iodine
Description: This is a mouth wash that can be used over the counter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate, povidone iodine
Description: This is a mouth wash that can be used over the counter.
Study: NCT06749262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking on incline or walking at increasing speed for 36 visits
Description: Subjects will be prepared for data collection by wearing an exercise suit and obtaining height and body weight. Breathing sensors and foot switches will be worn to measure breathing and walking performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking on incline or walking at increasing speed for 36 visits
Description: Subjects will be prepared for data collection by wearing an exercise suit and obtaining height and body weight. Breathing sensors and foot switches will be worn to measure breathing and walking performance.
Study: NCT06750744

Intervention type: RADIATION
Intervention: chest x ray
Description: chest X ray identify severity of pneumonia

Intervention type: RADIATION
Intervention: chest X ray
Description: chest radiological evaluation via x ray

Intervention type: DRUG
Intervention: Tigecycline (Tygacil)
Description: selective antibiogram
Study: NCT06748846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiotherapy + Occupational therapy + Focal Muscle Vibration
Description: - Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. -Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. -SMV (15 minutes): Administered during the last part of each physiotherapy session. Experimental Group: SMV is applied to the trapezius (middle/descending fibers) and quadratus lumborum bilaterally at 80 Hz with an amplitude of 0.5 mm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy + Occupational therapy + Sham Focal Muscle Vibration
Description: Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. SMV (15 minutes): Administered during the last part of each physiotherapy session. Control Group: Sham SMV using disconnected terminals produces sound but no vibration, ensuring blinding.
Study: NCT06748651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra
Description: Intra-articular injection of Allocetra performed once on Day 1 of the study
Study: NCT06749730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: adepelizumab ,1200mg, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib，250mg，QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w
Study: NCT06748339

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06750939

Intervention type: OTHER
Intervention: propofol
Description: The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,

Intervention type: OTHER
Intervention: propofol
Description: The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,
Study: NCT05190588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy
Description: Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
Study: NCT06442280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablet
Description: Dapagliflozin 10 mg 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin tablet
Description: Dapagliflozin 10 mg 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Solution, 1 Ml
Description: Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypertonic Saline Solution, 1 Ml
Description: Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: Furosemide 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Furosemide Injection
Description: Furosemide 20 mg
Study: NCT05757596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSA001 injection
Description: The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline, volume matched
Study: NCT06750939

Intervention type: OTHER
Intervention: ketamine
Description: The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,

Intervention type: OTHER
Intervention: ketamine
Description: The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,
Study: NCT06555003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Embolic Bead
Description: A minimum of 2 sessions of DEBIRI treatment and 2-4 cycles of systemic chemotherapy are administered (based on tumor size, bilobar or unilobar involvement of the liver, treatment response rate, treatment tolerance, occurrence of side effects, and liver function). Prior to performing DEBIRI, initial angiography is done via the femoral or axillary artery to determine the anatomy of the right and left hepatic arteries as well as the arteries supplying the tumor. Subsequently, a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor. The intervention will be repeated to deliver 200 mg of irinotecan intravascularly to the liver mass. A 14-day interval between the procedures is established to minimize side effects. Targeted therapy administration for each treatment group based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status as explained in control arm.
Study: NCT06751030

Intervention type: BEHAVIORAL
Intervention: The Mother Mentor program
Description: The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
Study: NCT06189690

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
Study: NCT06751030

Intervention type: DIAGNOSTIC_TEST
Intervention: GeneXpert HPV test
Description: A cervical cancer screening tool.
Study: NCT06749886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab, 120 mg subcutaneous injection, every 21-28 days a cycle, given on the first day, a loading dose is given on d8 of the first cycle, and continued use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Tislelizumab, 200 mg intravenous infusion, every 21 days a cycle, given on the first day, and continued use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 60 mg/m2 intravenous infusion, every 21 days a cycle, given on the first day, and continued use.
Study: NCT06748742

Intervention type: DRUG
Intervention: In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by the device
Description: In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by using the fluorescence imaging equipment that comes with the device. Guided by real-time fluorescence imaging, the urethra is precisely dissected and severed in front of the bladder neck. Through this improved operation, the bladder neck is protected, the neck injury that is common in conventional surgical operations is reduced, and the reconstructive surgical operations necessary after loss are reduced, and the surgical efficiency is improved. By protecting the bladder neck, the sphincter is better preserved, postoperative urinary incontinence is reduced, and the surgical outcome is improved.